According to study details released Friday as the U.S. considers opening vaccinations to that age group, kid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91per cent effective at preventing symptomatic infections in 5- to 11-year-olds. The shots could begin in early November with
Dr.Sunita Dube sets her goals right for empowering women with 10 point Program and Statue of Immunity Research Center Renowned Radiologist, Philanthropist, healthcare entrepreneur Dr.Sunita Dube is name to reckon for her revolutionizing work in the healthcare sector along with standing by the cause of Saving, educating
India has achieved a major milestone in its war against Covid-19 as increasing vaccinations in the country crossed the 100 crore mark on Thursday. After china, administering more than 200 crore doses, India is only the second country to have reach the landmark of 100 Crore
South Africa has started giving COVID-19 vaccinations to adolescents aged between 12 and 17 years, with a goal of inoculating at least 6 million people from this age group. The country is trying to increase its rate of vaccinations which is running behind the target of
On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) recommended the COVID-19 vaccine boosters for recipients of the Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N) shots, and said Americans can choose a different shot from their original inoculation as a booster. CDC director
A booster dose of the COVID-19 vaccine developed by Pfizer Inc (PFE.N) and German partner BioNTech SE (22UAy.DE) was 95.6% effective against the coronavirus when compared to a vaccinated group that did not get the third shot, data from a large study released by the companies showed on Thursday. The
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the launch of the Medtronic Open Innovation Platform (OIP) for APAC. The OIP will bring strategic collaboration in healthcare technologies from various innovators across the Asia-Pacific and several stakeholders across the healthcare ecosystem through
Children who contract a mild case of COVID-19 may not develop antibodies to the virus afterward, a study from Australia suggests. Researchers compared 57 children and 51 adults with mild COVID-19 or asymptomatic infections. Only 37% of children appeared to develop antibodies, compared to 76%
Japan's Shionogi & Co Ltd (4507.T) said on Wednesday it started a Phase II/III clinical trial for its COVID-19 vaccine candidate.The trial for the recombinant protein-based vaccine will take place in Japan and follows a Phase I trial in the country, Shionogi said in a statement. The
The U.S. Food and Drug Administration on Wednesday authorized booster doses of the COVID-19 vaccines from Moderna Inc (MRNA.O) and Johnson & Johnson (JNJ.N), and said Americans can choose a different shot from their original inoculation as a booster. That means all three vaccines authorized in
